Pharmaceutical company Pfizer has begun negotiations on a possible acquisition of biotech company Seagen. The transaction amount is estimated to be at least $30 billion. writer Wall Street Journal, with citation.
The publication noted that Pfizer is in talks to acquire biotech company Seagen, but negotiations are at an early stage. Therefore, “there is no guarantee that the transaction will occur.” For example, in 2022, the American pharmaceutical company Merck wanted to buy Seagen, but they did not lead to anything.
Seagen itself specializes in toxin immunoconjugates, which are drugs for the targeted treatment of tumors, according to the publication.
The WSJ added that with the successful acquisition of Seagen, Pfizer could reduce losses from the sale of its drugs as their patents expire in the next few years. Pfizer has predicted that by 2030, the company’s sales will fall by $17 billion.
Azamat Metov, general manager of the pharmaceutical company that owns the plant, at the end of December declarationIt has been reported that PharmAid company, which purchased a vaccine production facility in the Kaluga Region from Novamedica and Pfizer, will restart the construction of the facility in 2023.